Market revenue in 2023 | USD 62.8 million |
Market revenue in 2030 | USD 67.7 million |
Growth rate | 1.1% (CAGR from 2023 to 2030) |
Largest segment | Capping agents |
Fastest growing segment | Capping Agents |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Capping Agents, Nucleotides, Plasmid DNA, Enzymes |
Key market players worldwide | Roche Holding AG, Merck KGaA, Thermo Fisher Scientific Inc, Maravai LifeSciences Holdings Inc Ordinary Shares - Class A, New England Biolabs, Creative-Biolabs, Jena Bioscience, YEASEN Biotechnology, BOC Sciences, Hongene Biotechnology |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to mrna synthesis raw materials market will help companies and investors design strategic landscapes.
Capping agents was the largest segment with a revenue share of 39.01% in 2023. Horizon Databook has segmented the Australia mrna synthesis raw materials market based on capping agents, nucleotides, plasmid dna, enzymes covering the revenue growth of each sub-segment from 2018 to 2030.
Rising investments by the government organizations and market players in the country for the mRNA synthesis is expected to boost the demand for the raw materials required for it. Hence, several companies are launching innovative products and are partnering with vaccine manufacturers to provide the raw materials required for mRNA synthesis.
The major players in the country offering raw materials includes AcuraBio, Kaneka Eurogentec S.A., Southern RNA Pty Ltd, and many others. Owing to the rising awareness regarding mRNA vaccines in the country, companies are launching dedicated facilities for the mRNA vaccine manufacturing which is expected to boost the demand for the raw materials required for the mRNA synthesis in the region.
The facility is located at Monash, one of the largest universities in Australia, and is projected to manufacture around 100 million vaccine doses per year for influenza, COVID-19 and for other diseases.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia mrna synthesis raw materials market , including forecasts for subscribers. This country databook contains high-level insights into Australia mrna synthesis raw materials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account